|Ticker||Company name||Industry||Market Cap
|Dividend Yield||Dividend Frequency||Stock price||Currency||Stock Exchange|
|ROG||Roche Holding AG||Healthcare||258.98||3 %||Annual||300.25||CHF||SIX Swiss Exchange|
Company's Past Performance
The 5 years average P/E ratio is the average of each year’s P/E ratios. P/E ratio in any year is limited to 30 in order to reduce the effect of the extreme values on the average P/E.
Roche Holding AG is a research-based healthcare company. The Company develops, manufactures and delivers medicines, and diagnostic instruments and tests. Its operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. Its Pharmaceuticals division consists of two business segments: Roche Pharmaceuticals and Chugai. Its Diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. It develops medicines for the disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its product portfolio consists of Pharmaceuticals, Solutions for Diagnostics and Products for Researchers. Its Pharmaceutical products include ACTEMRA and CellCept. Its Solutions for Diagnostics products include Accu-Chek Active System and Accu-Chek Aviva Nano System. The Company’s Products for Researchers include Cedex HiRes and Genome Sequencer FLX System.